Literature DB >> 18080842

Molecular cloning and preliminary analysis of the human alpha-methylacyl-CoA racemase promoter.

Weiwen Chen1, Weifang Wu, Jian Zhao, Chunxiao Yu, Wenwen Liu, Anli Jiang, Jianye Zhang.   

Abstract

Alpha-methylacyl-CoA racemase (AMACR) is an enzyme involved in beta-oxidation of branched-chain fatty acids and bile acid intermediates. Recent works have revealed that AMACR is overexpressed in prostate cancer and functionally important for the growth of prostate cancer cells. Despite the recent interest in AMACR as a diagnostic marker for prostate cancer, little is known about the transcriptional regulation of AMACR in prostate cancer. To elucidate the regulation of the AMACR gene, a 2.3-kb fragment of its 5' flanking region was cloned into pGL3-Basic, then using tansfection and Dual-luciferase reporter assay, a preliminary analysis on promoter activity and function of this 2.3-kb sequence was carried out. This 2.3-kb fragment represented promoter activity that consistent with the expression level in LNCaP and PC-3 cells respectively. Transfection experiments of 5'-deletion mutants into LNCaP cells revealed a positive-regulatory region located between nucleotides -423 and -93 that may be responsible for AMACR transactivation in LNCaP cells. Cotransfection experiments revealed that promoter activity of this 2.3-kb sequence was down-regulated by C/EBPalpha, p53, NF-kappaB p50. And data from luciferase-based reporter assays suggest that the promoter function of AMACR is independent of androgen receptor-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18080842     DOI: 10.1007/s11033-007-9196-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  10 in total

1.  Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy.

Authors:  S Ferdinandusse; S Denis; P T Clayton; A Graham; J E Rees; J T Allen; B N McLean; A Y Brown; P Vreken; H R Waterham; R J Wanders
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

2.  Repression of the basal c-fos promoter by wild-type p53.

Authors:  N Kley; R Y Chung; S Fay; J P Loeffler; B R Seizinger
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

3.  Identification of a p53-dependent negative response element in the bcl-2 gene.

Authors:  T Miyashita; M Harigai; M Hanada; J C Reed
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

4.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

5.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.

Authors:  H Werner; E Karnieli; F J Rauscher; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

6.  Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.

Authors:  M Burchardt; T Burchardt; A Shabsigh; M Ghafar; M W Chen; A Anastasiadis; A de la Taille; A Kiss; R Buttyan
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

7.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.

Authors:  X Liu; C W Miller; P H Koeffler; A J Berk
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

8.  Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1.

Authors:  F Borellini; R I Glazer
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

9.  Wild-type p53 binds to the TATA-binding protein and represses transcription.

Authors:  E Seto; A Usheva; G P Zambetti; J Momand; N Horikoshi; R Weinmann; A J Levine; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein.

Authors:  K Okamoto; D Beach
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

  10 in total
  7 in total

1.  Functional analysis of pig myostatin gene promoter with some adipogenesis- and myogenesis-related factors.

Authors:  Bing Deng; Jianghui Wen; Yi Ding; Qishuang Gao; Haijun Huang; Zhiping Ran; Yunguo Qian; Jian Peng; Siwen Jiang
Journal:  Mol Cell Biochem       Date:  2011-12-11       Impact factor: 3.396

2.  High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Authors:  Adrian Box; Mohammed Alshalalfa; Samar A Hegazy; Bryan Donnelly; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-06-07

3.  Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-24       Impact factor: 4.553

4.  AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.

Authors:  Ying-En Lee; Hong-Lin He; Sung-Wei Lee; Tzu-Ju Chen; Kwang-Yu Chang; Chung-Hsi Hsing; Chien-Feng Li
Journal:  Tumour Biol       Date:  2014-05-16

5.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

6.  Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.

Authors:  Mariya Shapovalova; Julia Davydova; Christine Henzler; Mark Daniel; Scott M Dehm; Christopher A Warlick; Aaron M LeBeau
Journal:  Oncotarget       Date:  2018-11-30

7.  Suppression of α-methylacyl-coenzyme A racemase by miR200c inhibits prostate adenocarcinoma cell proliferation and migration.

Authors:  Hanbing Xie; Ling Nie; Mengni Zhang; Zhengzheng Su; Xueqin Chen; Miao Xu; Jing Gong; Ni Chen; Qiao Zhou
Journal:  Exp Ther Med       Date:  2019-12-31       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.